SCHEMBL22875375

SCHEMBL22875375

CC(C)(F)CC(=O)NC12CCC3C(C(=O)C=C4C5(C)C=C(C#N)C(=O)C(C)(C)C5CCC43C)C1CC(C)(C)CC2

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MBOAT4 Q96T53 4/20 0.52
▸ NOS2 P35228 8/20 0.49
▸ NFE2L2 Q16236 3/20 0.49
▸ CYP3A4 P08684 2/20 0.49
▸ CYP2C19 P33261 2/20 0.49
▸ KEAP1 Q14145 2/20 0.49
▸ USP7 Q93009 2/20 0.49
▸ USP2 O75604 1/20 0.49
▸ STAT3 P40763 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CCR6 P51684 1/20 0.43
▸ RORC P51449 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18973011 0.96 MBOAT4 (0.55) MBOAT4NOS2NFE2L2CYP3A4CYP2C19
SCHEMBL20171797 0.90 MBOAT4 (0.52) MBOAT4NOS2NFE2L2CYP3A4CYP2C19
SCHEMBL22875555 0.90 MBOAT4 (0.52) MBOAT4NOS2NFE2L2CYP3A4CYP2C19
SCHEMBL22875752 0.90 MBOAT4 (0.52) MBOAT4NOS2NFE2L2CYP3A4CYP2C19
SCHEMBL22875750 0.90 MBOAT4 (0.52) MBOAT4NOS2NFE2L2CYP3A4CYP2C19
SCHEMBL20171798 0.90 NOS2 (0.54) MBOAT4NOS2NFE2L2CYP3A4CYP2C19
SCHEMBL20750860 0.89 MBOAT4 (0.52) MBOAT4NOS2NFE2L2CYP3A4CYP2C19
SCHEMBL22875749 0.89 MBOAT4 (0.52) MBOAT4NOS2NFE2L2CYP3A4CYP2C19
SCHEMBL20171815 0.89 MBOAT4 (0.52) MBOAT4NOS2NFE2L2CYP3A4CYP2C19
SCHEMBL24512003 0.89 MBOAT4 (0.51) MBOAT4NOS2NFE2L2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3444261-B1 2,2-DIFLUOROPROPIONAMIDE DERIVATIVE OF BARDOXOLONE METHYL, PHARMACEUTICAL COMPOSITIONS AND POLYMORPHS THEREOF FOR USE IN TREATING CERTAIN CONDITIONS REATA PHARMACEUTICALS INC (US) 2021-01-13 — — EP disclosed
Send feedback